Podoplanin expression, peripheral blood count parameters, and biomarkers of blood coagulation
. | Podoplanin-positive tumors (+, ++, and +++), n = 151 . | Podoplanin-negative tumors (–), n = 62 . | P . | P* . |
---|---|---|---|---|
Platelet count, × 109/L | 227 (186-285) | 286 (241-355) | <.001 | .007† |
Hemoglobin, g/dL | 13.6 (13.0-14.5) | 13.9 (13.0-14.6) | .232 | .384 |
Leukocyte count, × 109/L | 8.68 (6.30-12.15) | 7.11 (5.36-10.55) | .029 | .289† |
sP-selectin, ng/mL | 36.8 (28.7-47.9) | 38.8 (28.8-51.2) | .513 | .637† |
D-dimer, μg/mL | 0.85 (0.46-1.92) | 0.42 (0.23-0.79) | <.001 | .001† |
F1+F2, pmol/L | 210 (154-325) | 194.5 (123-260) | .047 | .209† |
FVIII activity, % | 224 (156-295) | 179.5 (147-239) | .006 | .142 |
Peak thrombin generation, nM | 374 (198-552) | 284 (167-493) | .122 | .288 |
Fibrinogen, mg/dL | 319 (255-381) | 309 (268-381) | .889 | .832 |
. | Podoplanin-positive tumors (+, ++, and +++), n = 151 . | Podoplanin-negative tumors (–), n = 62 . | P . | P* . |
---|---|---|---|---|
Platelet count, × 109/L | 227 (186-285) | 286 (241-355) | <.001 | .007† |
Hemoglobin, g/dL | 13.6 (13.0-14.5) | 13.9 (13.0-14.6) | .232 | .384 |
Leukocyte count, × 109/L | 8.68 (6.30-12.15) | 7.11 (5.36-10.55) | .029 | .289† |
sP-selectin, ng/mL | 36.8 (28.7-47.9) | 38.8 (28.8-51.2) | .513 | .637† |
D-dimer, μg/mL | 0.85 (0.46-1.92) | 0.42 (0.23-0.79) | <.001 | .001† |
F1+F2, pmol/L | 210 (154-325) | 194.5 (123-260) | .047 | .209† |
FVIII activity, % | 224 (156-295) | 179.5 (147-239) | .006 | .142 |
Peak thrombin generation, nM | 374 (198-552) | 284 (167-493) | .122 | .288 |
Fibrinogen, mg/dL | 319 (255-381) | 309 (268-381) | .889 | .832 |
F1+F2, prothrombin fragment 1+2; FVIII, factor VIII.
Median levels and interquartile ranges are given. Unadjusted and adjusted P values for the comparison between podoplanin-positive and -negative tumors are given.
Adjusted for age, sex, and tumor type (WHO grade IV tumors vs others).
Dependent variables were log-transformed to increase model fit.